Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 8/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | PNLIP | P16233 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Horminone SCHEMBL22861860 | 0.85 | CYP19A1 (0.45) | CYP19A1FDPSEP300GGPS1PTGES | |
| Horminone SCHEMBL22861891 | 0.85 | CYP19A1 (0.45) | CYP19A1FDPSEP300GGPS1PTGES | |
| SCHEMBL30088312 | 0.75 | CYP19A1 (0.45) | CYP19A1FDPSEP300GGPS1PTGES | |
| SCHEMBL14303936 | 0.71 | EP300 (0.40) | CYP19A1FDPSEP300GGPS1 | |
| SCHEMBL14303934 | 0.68 | EP300 (0.35) | FDPSEP300 | |
| SCHEMBL22861892 | 0.68 | FDPS (0.39) | CYP19A1FDPSEP300GGPS1 | |
| SCHEMBL21291505 | 0.68 | EP300 (0.40) | CYP19A1FDPSEP300GGPS1PTGES | |
| Royleanone SCHEMBL21291506 | 0.67 | CYP3A4 (0.44) | CYP19A1FDPSEP300GGPS1PTGES | |
| Royleanone SCHEMBL16006778 | 0.67 | CYP3A4 (0.44) | CYP19A1FDPSEP300GGPS1PTGES | |
| SCHEMBL22861886 | 0.65 | EP300 (0.38) | CYP19A1FDPSEP300GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200368180-A1 | Deacetylnemorone Abietane Diterpenoids for Use in Cancer Treatment | NATIONAL SCIENCE FOUNDATION | 2020-11-26 | — | — | US | disclosed |
| US-10786468-B2 | Deacetylnemorone abietane diterpenoids for use in cancer treatment | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786468-B2 | Deacetylnemorone abietane diterpenoids for use in cancer treatment | NCEH1, DOHH, AMDHD2 | CYP19A1 385/4885FDPS 2732/4885EP300 2170/4885 |
| US-20200368180-A1 | Deacetylnemorone Abietane Diterpenoids for Use in Cancer Treatment | NCEH1, DOHH, AMDHD2 | CYP19A1 395/4885FDPS 2721/4885EP300 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.